Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
about
Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampusSynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholUpregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors.The acetylcholinesterase inhibitor BW284c51 is a potent blocker of Torpedo nicotinic AchRs incorporated into the Xenopus oocyte membrane.Cholinergic neurotransmission in the preBötzinger Complex modulates excitability of inspiratory neurons and regulates respiratory rhythmAllosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.An analysis of acetylcholinesterase sequence for predicting mechanisms of its non-catalytic actions.Functional characterization of AT-1001, an α3β4 nicotinic acetylcholine receptor ligand, at human α3β4 and α4β2 nAChRMorantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.Alzheimer's disease drugs: an application of the hormetic dose-response model.Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.Activation and block of the adult muscle-type nicotinic receptor by physostigmine: single-channel studies.Activation of heteroliganded mouse muscle nicotinic receptors.Mechanism of tacrine block at adult human muscle nicotinic acetylcholine receptors.Activation of nicotinic ACh receptors with alpha4 subunits induces adenosine release at the rat carotid body.Acute effects of physostigmine and galantamine on the binding of [18F]fluoro-A-85380: a PET study in monkeys.Determination of the Residues in the Extracellular Domain of the Nicotinic α Subunit Required for the Actions of Physostigmine on Neuronal Nicotinic Receptors.The E Loop of the Transmitter Binding Site Is a Key Determinant of the Modulatory Effects of Physostigmine on Neuronal Nicotinic α4β2 Receptors.
P2860
Q28360590-D7A18D43-7890-433A-B09B-1F918B73FF8AQ28818062-C0430AE1-28F6-4CF8-9C39-9C976D48E9AEQ33418312-93E930C8-ADBE-4C33-9BA0-A113C8B3164DQ34090985-F59C7B1B-4A25-495B-A445-F99ADE936508Q35048481-31D1D69F-426E-4223-BDC6-2CAD23FE0B25Q35125278-1A27E885-6ACF-42EB-884C-B20C4D9F6B33Q35182101-88CD50A2-61A4-48EB-803F-48D09D8F3AD8Q35841568-733796AB-5239-4637-91F7-0AB7C375627DQ36816827-4659BCFA-9006-4B24-8C0C-19970A54AFF1Q36982933-DB77D1C8-E394-4939-8687-2A184D84CF7EQ37196488-26D497DD-3086-4A98-8BE4-71A01E87B4B2Q39634128-ABD00F28-B03E-435C-B57F-081BFBA0D06EQ39975737-2043F758-3043-4856-A6BA-56F9AFDFAC27Q40457011-7FFEB2E7-BE18-42E9-A529-7D9C8E4021BAQ40708436-842BE852-E109-4867-BE57-1FB733C041C7Q41836383-75726501-C345-4D80-85D5-3AA484717778Q46415862-CC65F55C-A0D0-4DFD-BAED-AC73F9CB7FDEQ50935551-48E4D908-6BDA-408E-B188-29D72189FD5BQ51299120-8D42DC7C-F1EE-4503-A8CE-56D902420ACC
P2860
Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@en
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@nl
type
label
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@en
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@nl
prefLabel
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@en
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@nl
P2093
P2860
P1476
Competitive potentiation of ac ...... olinesterase-inhibiting drugs.
@en
P2093
C J Smulders
H P Vijverberg
R G van Kleef
P2860
P304
P356
10.1046/J.1471-4159.2000.0752492.X
P407
P577
2000-12-01T00:00:00Z